IFN-gamma / IFNG Antibody

IFN-gamma / IFNG Antibody

IFN-gamma / IFNG Antibody Product Information

• Immunogen: Recombinant human IFNG protein ( Catalog#11725-HNAC )
• Antibody Type: Rabbit Monoclonal Antibody ( Rabbit mAb Service Platform )
• Clone ID: 121
• Ig Type: Rabbit IgG
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: This antibody was obtained from a rabbit immunized with purified, human cell-derived, recombinant human IFNG ( rh IFNG ; Catalog#11725-HNAC ; NP_000610.2 ; Met 1 - Gln 166 ).

IFN-gamma / IFNG Antibody Usage Guide

• Specificity: Human IFN-gamma / IFNG
• Western blot: This antibody can be used at 1 - 2 μg/mL with the appropriate secondary reagents to detect human IFN-gamma in WB. Using a DAB detection system, the detection limit for human IFN-gamma is approximately 0.5 ng/lane under non-reducing conditions and reducing conditions
• Direct ELISA: This antibody can be used at 0.1 - 0.2 μg/mL with the appropriate secondary reagents to detect human IFN-gamma. The detection limit for human IFN-gamma is approximately 0.00245 ng/well
• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

IFN-gamma / IFNG Antibody Background

Interferon gamma, also known as IFN-gamma, Immune interferon and IFNG, is a secreted protein which belongs to the type I I (or gamma) interferon family. IFN-gamma / IFNG is produced by lymphocytes and activated by specific antigens or mitogens. IFN-gamma / IFNG, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I  interferons. Genetic variation in IFNG is associated with the risk of aplastic anemia (AA) which is a rare disease in which the reduction of the circulating blood cells results from damage to the stem cell pool in bone marrow. In most patients, the stem cell lesion is caused by an autoimmune attack. T-lymphocytes, activated by an endogenous or exogenous, and most often unknown antigenic stimulus, secrete cytokines, including IFN-gamma, which would in turn be able to suppress hematopoiesis.

References

1. Rinderknecht E. et al., 1984, J. Biol. Chem. 259:6790-7.
2. Landar A. et al., 2000, J. Mol. Biol. 299:169-79.
3. Dufour C. et al., 2004, Br. J. Haematol. 126:682-5.
4. Goshima N. et al., 2008, Nat. Methods 5:1011-7.